Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Bimatoprost (lashes) wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Prescription topical. Bimatoprost 0.03% is applied once daily as a thin line to the skin of the UPPER eyelid margin at the lash base (not to the lower lid, and avoid getting it in the eye), using a fresh applicator per eye. Continuous use is needed to maintain results. Use under a clinician, especially if you have glaucoma or take prostaglandin eye drops. There is no oral or systemic use. This library does not provide an ingestion protocol.
evening
Bimatoprost 0.03% solution (Latisse) with single-use applicators, under a clinician
Topical use, typically ~2-5% tranexamic acid in a serum applied to areas of melasma once or twice daily, alongside daily sunscreen. There is no oral or systemic dose in this cosmetic context — the ingested medication is a separate prescription use with clotting-risk considerations. This library does not provide an ingestion protocol.
any
Leave-on topical serum (≈2-5% tranexamic acid)
Throughout
8-16 weeks
2-6 months after stopping
Weeks to months
Throughout
8-12 weeks
Throughout
Throughout
Long-term safety and efficacy of bimatoprost solution 0.03% application to the eyelid margin for the treatment of idiopathic and chemotherapy-induced eyelash hypotrichosis: a randomized controlled trial.
Br J Dermatol (2015) · Rct
1-year double-masked RCT: composite primary endpoint (Global Eyelash Assessment + satisfaction) met for bimatoprost vs vehicle in idiopathic (40.2% vs 6.8%) and post-chemotherapy (37.5% vs 18.2%) hypotrichosis
Bimatoprost for eyelash growth in Japanese subjects: two multicenter controlled studies.
Aesthetic Plast Surg (2014) · Rct · n=209
Two double-masked vehicle-controlled RCTs (n=209: 173 idiopathic, 36 chemotherapy-induced) in Japanese subjects
The efficacy of topical prostaglandin analogs for hair loss: A systematic review and meta-analysis.
Front Med (Lausanne) (2023) · Meta analysis
Meta-analysis of six placebo-controlled RCTs of topical prostaglandin analogs (incl. bimatoprost) for hair growth (lashes, brows, scalp)
Topical tranexamic acid as a promising treatment for melasma.
J Res Med Sci (2014) · Rct · n=50
Double-blind 12-week split-face RCT in 50 women: 3% topical TXA on one side vs 3% hydroquinone + 0.01% dexamethasone on the other, twice daily
The effectiveness and safety of 3% tranexamic acid cream vs. 4% hydroquinone cream for mixed-type melasma in skin of color: a double-blind, split-face, randomized controlled trial.
Acta Dermatovenerol Alp Pannonica Adriat (2024) · Rct · n=20
Double-blind 8-week split-face RCT in 20 skin-of-color subjects comparing 3% topical TXA cream vs 4% hydroquinone cream
Tranexamic acid as a therapeutic option for melasma management: meta-analysis and systematic review of randomized controlled trials.
J Dermatolog Treat (2024) · Meta analysis
Meta-analysis of 22 RCTs (1280 patients) of TXA delivered orally, topically, or by injection for melasma
Bimatoprost (lashes) has a higher evidence score (8/10 vs 6/10) and wins in 2 of 3 categories.
No known interactions between Bimatoprost (lashes) and Tranexamic Acid (topical) have been documented in our database. However, always consult a healthcare provider before combining supplements.